November 17, 2024

German Biotechnology Days 2025

German Biotechnology Days 2025
Go back

BioRN will be the hosting Bioregion for the upcoming German Biotechnology Days, which will take place in Heidelberg on 9-10 April 2025. 
Over two days, the ‘Who’s Who’ of the biotechnology sector will meet in Heidelberg to experience an exciting programme and take advantage of the numerous networking opportunities. BioRN will support BioDeutschland e.V as coordinator and organiser in providing innovative small and medium-sized biotechnology companies and their partners from industry, science, politics and society in Germany with a forum for knowledge exchange and networking.

It is also a great opportunity for our region to showcase the excellence and performance of our regional life science ecosystem to the world! 
Around 1000 guests from 21 nations are expected again and for the first time the conference language will be completely in English.

Join uns on the expo floor and book your stand. The following link will take you directly to the sponsoring packages: https://www.biotechnologietage.de/sponsoring/registration.html 

Our latest News

discover more
Digital recording of health status

Digital recording of health status

Successful pilot project at Heidelberg University Hospital Regularly surveying patients about their health-related quality of life is a key aspect of patient-centred medicine. At Heidelberg University Hospital, a new digital system is being used for this purpose in a pilot project: patients complete online questionnaires on their own mobile devices, after which the data is […]

read more
A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities. Dry eye disease, also referred […]

read more
Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Foster City, Calif., and Munich, Germany – April 7, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need. The acquisition significantly […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp